Core Viewpoint - The innovative intracranial injection method for oncolytic virus therapy enhances the convenience of treating brain tumors, demonstrating safety and efficacy in treating pediatric diffuse intrinsic pontine glioma (DIPG) with the new oncolytic virus Ad-TD-nsIL12 [1][6] Group 1: Oncolytic Virus Therapy - Oncolytic virus therapy is emerging as a disruptive new strategy for cancer treatment, with the potential to revolutionize clinical practices [2] - This therapy selectively infects and destroys tumor cells while activating the immune system, providing a dual mechanism of action against tumors [3][4] - The engineered oncolytic virus is designed to replicate specifically within tumor cells, minimizing harm to normal cells and enhancing therapeutic efficacy [5] Group 2: Mechanism and Design - The oncolytic virus used in the study is based on human adenovirus type 5 (Ad5) and has undergone genetic modifications to improve targeting and reduce toxicity [5] - Key genetic deletions enhance the virus's ability to kill tumor cells and improve the presentation of tumor-specific antigens to the immune system [5] - The introduction of non-secretory interleukin-12 (IL-12) maintains normal levels in the bloodstream, promoting systemic anti-tumor immunity while avoiding side effects from elevated IL-12 levels [5] Group 3: Clinical Trials and Results - Clinical trials have confirmed the safety of the oncolytic virus Ad-TD-nsIL12, with significant preclinical and clinical evidence supporting its effectiveness [6] - Over 200 oncolytic virus-related clinical trials are currently underway globally, with a significant portion originating from China [7] - Notable results from CG Oncology's phase 3 trial showed complete tumor disappearance in 82 out of 110 patients treated with their oncolytic virus therapy [7] Group 4: Future Directions - To accelerate the clinical translation of oncolytic virus therapy, collaboration between basic and clinical research is essential, along with enhanced communication among researchers and clinicians [7] - Future studies will explore the combination of oncolytic virus therapy with surgery, radiotherapy, and antibody treatments to address the heterogeneity of malignant tumors [8]

Core Viewpoint - The innovative intracranial injection method for oncolytic virus therapy enhances the treatment of brain tumors, demonstrating safety and efficacy in treating pediatric diffuse intrinsic pontine glioma (DIPG) [1][6]. Group 1: Oncolytic Virus Therapy - Oncolytic virus therapy is emerging as a disruptive new strategy for cancer treatment, with the potential to revolutionize clinical approaches [2]. - This therapy utilizes engineered viruses that selectively infect and destroy tumor cells while activating the immune system, providing a dual mechanism of action [3][4]. - The modified oncolytic virus (Ad-TD-nsIL12) shows improved targeting of tumor cells and reduced toxicity to normal cells through specific genetic alterations [5][6]. Group 2: Clinical Trials and Efficacy - Recent clinical trials have confirmed the safety of the oncolytic virus Ad-TD-nsIL12, with significant preclinical and clinical evidence supporting its effectiveness [6]. - Global statistics indicate over 200 ongoing clinical trials related to oncolytic viruses, with a substantial portion originating from China, highlighting the rapid advancement in this field [7]. - A notable study demonstrated that a new oncolytic virus (VG161) significantly extended the median overall survival of patients with recurrent liver cancer from 9.4 months to 17.3 months [7]. Group 3: Future Directions - The focus for future research includes enhancing collaboration between basic and clinical research to facilitate the transition of oncolytic virus therapies into clinical practice [7]. - The team plans to explore combination therapies involving oncolytic viruses with surgery, chemotherapy, and antibody treatments to address the heterogeneity of malignant tumors [8].